Bordetella bronchiseptica

The Bordetella bronchiseptica vaccine provides cats with protection against a significant bacterial pathogen that contributes to feline upper respiratory disease complex. Bordetella bronchiseptica is a gram-negative bacterium that can infect the respiratory tract of cats, causing clinical signs ranging from mild sneezing and nasal discharge to severe pneumonia, particularly in young kittens and immunocompromised individuals. Unlike the core vaccines recommended for all cats, the Bordetella vaccine is classified as a non-core or lifestyle vaccine, meaning its use is recommended based on individual risk assessment rather than as a universal recommendation. Cats living in high-density environments such as shelters, catteries, and boarding facilities face significantly higher exposure risk and are the primary candidates for this vaccination.

The feline Bordetella bronchiseptica vaccine currently available is administered intranasally, delivering modified live bacteria directly to the respiratory mucosa where infection naturally occurs. This route of administration offers distinct advantages for protection against respiratory pathogens, as it stimulates local mucosal immunity at the site of natural infection. The intranasal approach bypasses potential interference from maternal antibodies in young kittens and provides rapid onset of local protection, which can be particularly valuable in high-risk situations where immediate exposure is anticipated. The modified live nature of the vaccine means the bacteria can briefly replicate in the nasal passages, stimulating a robust immune response without causing significant disease in healthy cats.

Bordetella bronchiseptica is notable for its ability to infect multiple species, including dogs, cats, pigs, rabbits, and occasionally humans. The bacterium is closely related to Bordetella pertussis, which causes whooping cough in humans, though cross-species transmission of the exact same strains is complex. In multi-species households, particularly those with both dogs and cats, Bordetella can potentially transmit between species, though the clinical significance of this transmission varies. Dogs are commonly vaccinated against Bordetella as part of kennel cough prevention, and similar principles of exposure risk assessment apply to feline vaccination decisions. Understanding the bacterium's behavior in different species helps inform prevention strategies in mixed-species environments.

The decision to vaccinate cats against Bordetella bronchiseptica should be made collaboratively between the veterinarian and cat owner based on individual risk factors and lifestyle considerations. Cats with limited exposure to other cats and who do not visit high-density environments may not benefit significantly from vaccination, while cats in shelters, breeding facilities, or multi-cat households face sufficient risk to warrant protection. The vaccine has a good safety profile when administered appropriately, though the intranasal route may cause temporary mild upper respiratory signs as the modified live bacteria stimulate local immunity. Veterinary guidance ensures appropriate patient selection and proper administration technique for optimal outcomes.

The primary indication for the feline Bordetella bronchiseptica vaccine is prevention of respiratory disease caused by this bacterial pathogen in cats at elevated risk of exposure. Bordetella bronchiseptica is one of several infectious agents that can cause or contribute to the feline upper respiratory disease complex, a syndrome characterized by sneezing, nasal discharge, conjunctivitis, and sometimes more severe respiratory compromise. While viral pathogens such as feline herpesvirus and calicivirus are the primary causes of feline upper respiratory disease, Bordetella bronchiseptica can act as a primary pathogen or, more commonly, as a secondary invader that complicates viral infections. Vaccination helps reduce the impact of this bacterial component of respiratory disease in susceptible cat populations.

Shelter cats represent a primary target population for Bordetella vaccination due to the high-density, high-stress environment that facilitates disease transmission. Shelters often experience outbreaks of upper respiratory disease that spread rapidly through populations of unvaccinated or incompletely vaccinated cats. Bordetella bronchiseptica can contribute to these outbreaks, causing primary disease or worsening the severity of concurrent viral infections. Many shelter medicine protocols include Bordetella vaccination as part of intake procedures for all incoming cats, recognizing that the shelter environment creates uniquely elevated exposure risk. The intranasal vaccine's rapid onset of action makes it particularly suitable for shelter situations where immediate protection is needed.

Catteries and breeding facilities similarly benefit from Bordetella vaccination programs. These environments involve concentrated cat populations, introduction of new cats for breeding, and the presence of immunologically naive kittens who are particularly susceptible to respiratory infections. Bordetella bronchiseptica can cause severe disease in young kittens, potentially progressing to life-threatening bronchopneumonia. Protecting breeding queens before parturition and vaccinating kittens at appropriate ages helps reduce disease incidence in cattery populations. Many responsible breeders include Bordetella vaccination in their health protocols, particularly if they have experienced respiratory disease problems or if they introduce cats from outside sources.

Cats entering boarding facilities or grooming salons may benefit from Bordetella vaccination, particularly if the facility houses multiple cats in close proximity. Some boarding facilities require proof of Bordetella vaccination before accepting cats, similar to kennel cough vaccine requirements common in dog boarding. Even facilities that do not mandate vaccination may recommend it for cats who board frequently or for extended periods. The stress of boarding can compromise immune function, making cats more susceptible to respiratory infections they might otherwise resist. Pre-exposure vaccination provides protection during these vulnerable periods when cats face both increased exposure risk and decreased immune resistance.

Multi-cat households with dynamic populations, such as foster homes or households that regularly introduce new cats, represent another situation where Bordetella vaccination may be beneficial. When new cats enter a household, they may carry respiratory pathogens including Bordetella bronchiseptica, potentially introducing disease to resident cats. Households that experience recurrent respiratory disease problems despite appropriate FVRCP vaccination may benefit from adding Bordetella vaccination to their protocols. The decision to vaccinate in multi-cat households should consider the frequency of new introductions, the presence of young kittens or immunocompromised cats, and the history of respiratory disease in the household. Veterinary consultation helps determine whether Bordetella vaccination adds meaningful protection for specific household situations.

The feline Bordetella bronchiseptica vaccine is administered intranasally, a route that delivers the modified live bacteria directly to the respiratory mucosa where natural infection occurs. This administration route differs significantly from the subcutaneous injections used for most other feline vaccines and requires specific technique for optimal effectiveness. The intranasal approach stimulates local mucosal immunity, providing protection at the site where Bordetella bronchiseptica first contacts the respiratory system. Understanding proper administration ensures that cats receive the full protective benefit of vaccination while minimizing any adverse effects associated with the procedure.

The vaccination protocol for Bordetella bronchiseptica involves administering a single intranasal dose to cats 8 weeks of age or older. Unlike many other vaccines that require a multi-dose initial series, the intranasal Bordetella vaccine typically provides protection following a single administration due to the direct mucosal stimulation it provides. This single-dose protocol makes the vaccine particularly practical for shelter situations where cats may have limited time for completing multi-dose series. The vaccine is reconstituted according to manufacturer instructions immediately before administration, as the modified live bacteria begin to deteriorate once the vaccine is prepared. Prompt administration following reconstitution ensures optimal vaccine viability.

Intranasal administration requires gentle but effective technique to ensure vaccine contacts the nasal mucosa. The cat should be appropriately restrained, and the head positioned to allow nasal access. The vaccine is dispensed as drops into one or both nostrils, depending on the volume and manufacturer instructions. Some sneezing or head shaking following administration is normal and expected as the cat reacts to the sensation of liquid in the nasal passages. Veterinary staff should be prepared for this response and should ensure the vaccine has been administered before releasing the cat. Allowing the cat to sneeze out a significant portion of the vaccine before it contacts the mucosa can reduce effectiveness.

Booster vaccination recommendations for Bordetella bronchiseptica vary based on ongoing risk assessment. For cats in continuously high-risk environments such as shelters or catteries, annual revaccination is typically recommended to maintain protection. Cats who board occasionally may benefit from boosters administered shortly before anticipated exposure rather than on a fixed annual schedule. The timing of booster vaccination should consider the expected risk period, with protection ideally established before exposure occurs. Veterinarians can provide guidance on appropriate booster timing based on individual cat circumstances and anticipated activities.

Timing considerations are important for cats entering high-risk situations. The intranasal vaccine provides relatively rapid onset of local immunity, typically within 72 hours of administration, though full protection may take slightly longer to develop. Ideally, cats should be vaccinated at least one week before entering situations of increased exposure such as boarding facilities or shelter environments. However, the rapid onset of local immunity means that even immediate pre-exposure vaccination provides some benefit compared to no vaccination. For shelter intake, vaccination upon entry provides protection against exposure during the shelter stay even though some exposure may have already occurred during the intake process.

Special populations require consideration when determining vaccination protocols. Very young kittens under 8 weeks of age should not receive the vaccine due to their immature immune systems. Pregnant queens can receive the vaccine if the risk of Bordetella exposure outweighs the theoretical risks of vaccination during pregnancy, though ideally vaccination should be completed before breeding. Cats with active upper respiratory disease should generally have vaccination deferred until they recover, as the mucosal inflammation associated with active infection may affect vaccine response. Veterinary guidance helps navigate these special circumstances while maintaining appropriate protection for at-risk cats.

The feline Bordetella bronchiseptica vaccine has a generally favorable safety profile, with most cats experiencing no adverse effects or only mild, transient reactions related to the intranasal administration route. Understanding potential side effects helps cat owners distinguish expected responses from reactions requiring veterinary attention. The modified live nature of the vaccine and its direct mucosal administration mean that some local effects are predictable and represent normal immune stimulation rather than adverse events. Proper patient selection and administration technique minimize the likelihood of significant problems.

Mild upper respiratory signs represent the most commonly observed effects following intranasal Bordetella vaccination and are considered expected responses rather than true adverse events. Cats may develop sneezing, mild nasal discharge, or watery eyes within a few days of vaccination as the modified live bacteria briefly replicate in the nasal passages and stimulate local immune responses. These signs typically resolve within one week without treatment and do not indicate actual Bordetella disease. Cat owners should be informed to expect these mild symptoms and reassured that they represent the vaccine working as intended. The temporary discomfort is generally minimal and vastly preferable to actual Bordetella infection.

Local reactions at the administration site are inherently different for intranasal vaccines compared to injectable products. There is no injection site lump or soreness to monitor since the vaccine is delivered to the nasal mucosa. However, some cats may experience temporary nasal discomfort, increased sneezing frequency, or mild congestion following administration. These effects should be mild and self-limiting. If significant nasal congestion develops that affects the cat's ability to eat or breathe comfortably, veterinary evaluation is warranted to rule out concurrent respiratory infection or unusually severe vaccine response.

More significant adverse effects are uncommon but can occur. Some cats may develop more pronounced respiratory signs that persist beyond one week or that significantly affect their comfort or function. While rare, progression to actual bacterial infection requiring treatment has been reported, particularly in cats who may have been immunocompromised or harboring subclinical infections at the time of vaccination. Fever, severe lethargy, significant appetite loss, or labored breathing following vaccination warrant veterinary evaluation. These signs could indicate either unusual vaccine reaction or concurrent illness that coincidentally developed around the time of vaccination.

Systemic adverse effects from intranasal Bordetella vaccination are rare because the vaccine is designed to stimulate local mucosal immunity rather than systemic responses. Unlike injectable vaccines that can occasionally cause anaphylactic reactions, the intranasal route has minimal association with immediate hypersensitivity responses. However, any cat displaying signs of allergic reaction such as facial swelling, hives, or difficulty breathing should receive immediate veterinary attention. Cats who experience significant adverse effects following Bordetella vaccination should have these reactions documented in their medical records, and the need for future vaccination should be carefully weighed against the risks in consultation with the veterinarian. For most cats, the vaccine produces no significant adverse effects and provides valuable protection against a potentially serious respiratory pathogen.

While the Bordetella bronchiseptica vaccine is safe for most cats at elevated exposure risk, certain circumstances may contraindicate vaccination or warrant careful consideration before proceeding. Understanding these contraindications helps veterinarians select appropriate candidates for vaccination and ensures that cats receive the vaccine only when the benefits clearly outweigh any potential risks. Because Bordetella vaccination is a non-core recommendation rather than a universal requirement, risk-benefit assessment is particularly relevant in determining whether individual cats should receive this vaccine.

Cats currently experiencing upper respiratory disease should generally not receive the intranasal Bordetella vaccine until they have recovered. Active respiratory infection creates mucosal inflammation and immune activation that may interfere with vaccine response and could potentially worsen clinical signs. Additionally, administering an intranasal vaccine to a cat already struggling with respiratory symptoms adds additional irritation to compromised airways. Vaccination should be deferred until the cat has recovered, typically waiting at least one to two weeks after resolution of clinical signs. In shelter situations where immediate vaccination is desired upon intake, cats presenting with active respiratory disease may need to be isolated and have vaccination deferred until their condition improves.

Severely immunocompromised cats require careful consideration before receiving modified live vaccines, including the intranasal Bordetella product. Cats with advanced feline leukemia virus or feline immunodeficiency virus infections causing clinical immunosuppression may be unable to control even attenuated vaccine organisms, potentially developing actual disease from the modified live bacteria. Similarly, cats receiving high-dose immunosuppressive medications such as corticosteroids or chemotherapy drugs may be at increased risk from modified live vaccines. The decision to vaccinate immunocompromised cats should weigh the risk of exposure to virulent Bordetella against the potential for vaccine-associated disease. In many cases, reducing exposure risk through environmental management may be preferable to vaccination in severely immunocompromised individuals.

Very young kittens under 8 weeks of age should not receive the Bordetella vaccine due to their immature immune systems and potential for adverse effects. While young kittens are particularly susceptible to severe Bordetella disease, the vaccine is not labeled or recommended for this age group. Protection of very young kittens should focus on maintaining maternal antibody protection through vaccination of queens before breeding, reducing exposure through separation from potentially infected cats, and maintaining good environmental hygiene. Once kittens reach 8 weeks of age, they can receive the vaccine if their exposure risk warrants it.

Cats with known hypersensitivity to vaccine components should not receive products to which they have reacted previously. While true allergic reactions to intranasal Bordetella vaccines are uncommon, any cat who has experienced significant adverse reactions should be evaluated carefully before revaccination. The non-core status of this vaccine means that cats with vaccine sensitivities may reasonably forgo Bordetella vaccination if their exposure risk can be adequately managed through other means. Documentation of any adverse reactions helps inform future vaccination decisions and allows veterinarians to make appropriate recommendations for individual patients.

Understanding potential interactions between the Bordetella bronchiseptica vaccine and other medications or treatments helps optimize vaccination timing and patient outcomes. While the vaccine itself does not have traditional pharmacological interactions with most medications, certain treatments can affect immune response to vaccination, potentially reducing protection. Complete disclosure of all medications and treatments a cat is receiving allows veterinarians to make informed decisions about vaccination timing and to set appropriate expectations for vaccine effectiveness.

Immunosuppressive medications represent the most significant concern regarding vaccine response. Corticosteroids at immunosuppressive doses can impair the immune system's ability to respond to vaccines, potentially reducing the protective immunity developed following vaccination. Cats receiving high-dose prednisone, prednisolone, dexamethasone, or other corticosteroids may not mount adequate mucosal immune responses to intranasal Bordetella vaccination. The impact varies based on drug, dose, and duration of treatment. When possible, vaccination should be scheduled during periods of minimal immunosuppression, or timing should be coordinated with the prescribing veterinarian. For cats requiring ongoing immunosuppressive therapy, the risk-benefit balance of vaccination should be carefully evaluated.

Other immunosuppressive agents similarly affect vaccine response. Cyclosporine, chemotherapy drugs, and other immunomodulating medications can reduce the immune system's ability to respond to vaccination. Cats undergoing cancer treatment or receiving immunosuppressive therapy for immune-mediated diseases may have suboptimal responses to Bordetella vaccination. These cats also face increased risk from modified live vaccine organisms if their immune suppression is severe. Coordination between the primary veterinarian and any specialists managing the cat's underlying conditions helps determine appropriate vaccination timing and whether vaccination is advisable at all for severely immunocompromised patients.

Antibiotics may potentially affect response to modified live bacterial vaccines like the Bordetella product. Antibiotics active against Bordetella bronchiseptica could theoretically kill the vaccine organisms before they adequately stimulate immunity. If a cat is receiving antibiotics at the time of vaccination, the effectiveness of the vaccine may be compromised. Ideally, vaccination should be delayed until antibiotic treatment is completed, or antibiotic selection should consider potential interference with planned vaccination. This interaction is most relevant when antibiotics are being used to treat respiratory infections, the same condition the vaccine is designed to prevent. Veterinary guidance helps navigate the timing of vaccination relative to antibiotic therapy.

Concurrent administration of other vaccines does not appear to create problematic interactions with intranasal Bordetella vaccination. The intranasal route stimulates local mucosal immunity through a pathway distinct from the systemic immune responses generated by injectable vaccines. FVRCP, rabies, and other vaccines can generally be administered at the same veterinary visit as Bordetella, though they should be given at different sites (injectable vaccines subcutaneously in designated locations, Bordetella intranasally). Some veterinarians prefer to separate the timing of multiple vaccines in cats with histories of vaccine reactions or in debilitated patients, allowing clear identification of any vaccine that might cause adverse effects.

Appropriate precautions during and after Bordetella vaccination help ensure optimal outcomes while maximizing the protection this vaccine provides to cats at elevated exposure risk. Understanding what to expect and how to monitor vaccinated cats allows owners to distinguish normal post-vaccination responses from problems requiring veterinary attention. These precautions, combined with proper patient selection and administration technique, optimize the safety and effectiveness of vaccination.

Pre-vaccination assessment helps identify cats who may not be suitable candidates for Bordetella vaccination. Veterinarians typically perform at least a brief physical examination before vaccinating, paying particular attention to respiratory status since the vaccine is administered intranasally. Cats with nasal congestion, active sneezing, or other respiratory symptoms may need to defer vaccination until these signs resolve. Any history of adverse reactions to previous vaccinations should be discussed, and the cat's overall health status and immune function should be considered. Cats in good general health tolerate the vaccine well, while those with significant concurrent illness may need individualized assessment.

Post-vaccination monitoring for the intranasal Bordetella vaccine differs from injectable vaccine monitoring. Rather than watching for injection site reactions or immediate hypersensitivity, attention focuses on respiratory signs that may develop over the following days. Mild sneezing and nasal discharge are expected and should not cause concern unless they are severe or persistent. Cat owners should monitor for signs of significant respiratory distress, fever, severe lethargy, or loss of appetite, which could indicate unusual vaccine reaction or concurrent illness. Most cats show minimal to no observable effects following vaccination, and those who do develop mild respiratory signs typically recover within a week without intervention.

Multi-cat household considerations are particularly relevant for Bordetella vaccination due to the potential for vaccine virus shedding. The modified live bacteria in the vaccine can briefly replicate in the nasal passages and may be shed in respiratory secretions for a short period following vaccination. While this shedding is generally not significant enough to cause disease in healthy cats, severely immunocompromised household members could theoretically be affected. In households containing cats with advanced FeLV or FIV disease or cats receiving chemotherapy, recently vaccinated cats should be separated from immunocompromised individuals for several days following vaccination as a precautionary measure.

Timing of vaccination relative to anticipated exposure should be planned for optimal protection. The intranasal vaccine provides relatively rapid onset of local immunity, but ideally cats should be vaccinated at least one week before entering high-risk situations such as boarding facilities or shelter environments. Last-minute vaccination still provides benefit but may not allow time for full immunity to develop before exposure. For cats who board frequently, establishing a regular booster schedule ensures continuous protection. For cats with occasional boarding needs, scheduling vaccination before planned boarding allows time for immunity while avoiding unnecessary vaccination when risk is low.

Special populations warrant additional precautions. Pregnant cats should ideally be vaccinated before breeding rather than during pregnancy, though the vaccine can be given during pregnancy if exposure risk is high. Very young kittens under 8 weeks should not be vaccinated. Geriatric cats and those with chronic diseases should have their overall health considered when making vaccination decisions. The non-core status of this vaccine means that individual risk-benefit assessment is appropriate for every cat, and not all cats at theoretical risk necessarily need vaccination if their actual exposure can be adequately managed through other means.

Proper storage and handling of the Bordetella bronchiseptica vaccine is essential for maintaining vaccine potency and ensuring vaccinated cats receive effective protection. As a modified live bacterial vaccine, proper handling is particularly critical because the live organisms must remain viable to stimulate protective immunity. While cat owners do not typically handle vaccines directly, understanding storage requirements provides confidence that vaccines administered at veterinary facilities have been properly maintained throughout the supply chain.

Temperature control is the most critical aspect of vaccine storage. The Bordetella vaccine requires refrigeration at 35-45°F (2-7°C) and must be protected from both freezing and excessive heat. Live vaccine organisms are particularly sensitive to temperature extremes, and even brief exposure to inappropriate temperatures can kill the bacteria, rendering the vaccine ineffective. Unlike killed vaccines where potency might gradually decline with improper storage, modified live vaccines can be completely inactivated by temperature excursions. Veterinary practices use pharmaceutical-grade refrigerators with temperature monitoring to ensure consistent proper storage, and staff should verify cold chain maintenance upon receipt of vaccine shipments.

Light protection is another important storage consideration. The vaccine should remain in its original packaging until immediately before use, as manufacturer packaging is designed to protect contents from light exposure that can damage live bacterial organisms. During preparation for administration, vaccines should be kept away from direct sunlight and bright artificial light. The short interval between preparation and administration minimizes light exposure, but vaccines should not be left out on countertops under bright lights for extended periods.

Reconstitution and timing requirements are particularly important for modified live vaccines. The Bordetella vaccine is typically supplied as a lyophilized (freeze-dried) component that must be reconstituted with a diluent before administration. Once reconstituted, the live bacteria begin to deteriorate, and the vaccine should be administered promptly. Manufacturer recommendations typically specify using reconstituted vaccine within one hour, and veterinary staff should prepare the vaccine only when the patient is ready for administration. Any unused reconstituted vaccine should be discarded rather than saved for later use, as potency cannot be guaranteed once the product has been prepared.

Proper handling during administration ensures both patient safety and vaccine effectiveness. Aseptic technique prevents contamination, and staff should verify expiration dates before use. The intranasal administration route requires appropriate technique to ensure vaccine contacts the nasal mucosa adequately. Staff should be prepared for the cat to sneeze following administration and should ensure the vaccine has been properly delivered before releasing the patient. Proper documentation of vaccination, including product information, lot number, and administration date, maintains records necessary for tracking booster needs and responding to any adverse events or recall situations.

The Bordetella bronchiseptica vaccine is appropriate for cats of all breeds when individual risk assessment indicates vaccination is warranted. Unlike some medications where specific breeds show altered sensitivity or metabolism, there are no established breed-specific contraindications or required modifications for Bordetella vaccination. All cats at elevated exposure risk can benefit from protection against this respiratory pathogen, regardless of their breed background. However, certain breed characteristics and typical uses may influence vaccination decisions and the approach to administration.

Brachycephalic breeds such as Persians, Himalayans, and Exotic Shorthairs deserve consideration when administering intranasal vaccines. These flat-faced breeds have altered upper respiratory anatomy that may make intranasal administration technically more challenging and may increase the likelihood or severity of transient respiratory signs following vaccination. The narrowed nasal passages of brachycephalic cats may already compromise airflow, and any additional nasal irritation from vaccination could be more noticeable in these breeds. Despite these considerations, brachycephalic cats at elevated Bordetella exposure risk can still receive the vaccine, though veterinarians may monitor these patients more closely following administration.

Breed cats involved in showing face elevated exposure risk that may warrant Bordetella vaccination regardless of breed. Cat shows bring together large numbers of cats from various sources, creating conditions conducive to respiratory pathogen transmission. Many show cats travel frequently and contact unfamiliar cats regularly, maintaining continuous exposure risk. Some show organizations or venues may require or recommend Bordetella vaccination, similar to respiratory vaccine requirements common in dog shows. Show breeders should discuss vaccination protocols with their veterinarians based on their show schedules and the typical respiratory disease challenges in their breed communities.

Cattery and breeding program considerations often outweigh breed-specific factors in vaccination decisions. Breeding facilities of any breed may benefit from Bordetella vaccination protocols if they introduce cats from outside sources, maintain larger populations, or have experienced respiratory disease problems. The presence of young kittens increases the importance of respiratory disease prevention, as kittens are most susceptible to severe Bordetella infection. Some purebred lines may have documented family histories of vaccine sensitivities that warrant consideration, though these are individual variations rather than breed-wide characteristics.

Size variations among cat breeds do not significantly affect Bordetella vaccination protocols. Unlike medications dosed by body weight, vaccine doses are standardized regardless of cat size because immune response depends on vaccine antigen content rather than body mass. Small breeds like the Singapura and large breeds like the Maine Coon receive the same vaccine dose with equivalent expected immune responses. The intranasal route minimizes any size-related considerations that might apply to injectable vaccines, as the vaccine is delivered directly to the target tissue regardless of the cat's overall body size.

Understanding the Bordetella bronchiseptica vaccine's place within feline respiratory disease prevention helps veterinarians and cat owners develop comprehensive protection strategies. Bordetella vaccination represents one component of respiratory disease management in cats, complementing other vaccines and health practices that together provide optimal protection. The non-core status of this vaccine means that its use should be integrated thoughtfully with other preventive measures based on individual risk assessment.

The FVRCP vaccine provides the foundation of respiratory disease prevention in cats and should be current before considering additional respiratory vaccines like Bordetella. FVRCP protects against feline herpesvirus-1 and feline calicivirus, the primary viral causes of upper respiratory disease, as well as panleukopenia. While FVRCP and Bordetella vaccines address different pathogens, they work together to reduce the overall burden of respiratory disease in at-risk populations. In shelter and cattery settings where respiratory disease is a significant concern, both vaccines are typically included in prevention protocols. FVRCP remains a core vaccine for all cats, while Bordetella is added when risk assessment indicates need.

The Chlamydophila felis vaccine is another non-core respiratory vaccine that may be considered alongside Bordetella in high-risk populations. Chlamydophila felis causes conjunctivitis and upper respiratory signs in cats and, like Bordetella, spreads readily in high-density environments. Some catteries and shelters include both Chlamydophila and Bordetella vaccines in their protocols when respiratory disease pressure is high. The decision to add either or both of these non-core vaccines depends on the specific disease challenges faced by the cat population in question. Veterinary guidance helps determine which vaccines provide meaningful benefit for specific situations.

Combination vaccine products may include Bordetella with other antigens in some formulations. Some manufacturers produce intranasal vaccines combining Bordetella bronchiseptica with feline herpesvirus and calicivirus components, providing respiratory protection through a single intranasal administration. These combination intranasal products offer convenience and may provide advantages in mucosal immunity stimulation for all three pathogens. The choice between single-agent and combination intranasal vaccines depends on the specific protection needed, the cat's vaccination history, and product availability. Veterinarians can advise on the most appropriate product selection for individual patients.

Supportive measures complement vaccination in respiratory disease prevention. Good ventilation in multi-cat environments, appropriate population density management, isolation of symptomatic cats, and proper sanitation all reduce disease transmission regardless of vaccination status. Cats with chronic respiratory conditions may benefit from nutritional support, stress reduction, and other health-promoting practices alongside appropriate vaccination. A comprehensive approach addressing both vaccination and environmental management provides the strongest protection against respiratory disease in high-risk feline populations.